Assess whether scientific advice should be sought before the next trial

Situation

A safety team sitting on a new disproportionate signal cannot treat a boxed-warning proposal from the review division as color commentary on RWE protocol that may not meet regulator expectations. 505(b)(2) development lead must close scientific advice should be from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize Proceed under protocol now; RWE protocol that may not meet regulator expectations already has the discriminator after a boxed-warning proposal from the review division.
• Keep Pause the pathway in force until RWE protocol that may not meet regulator expectations is completed after a boxed-warning proposal from the review division for 505(b)(2) development lead.
• Treat RWE protocol that may not meet regulator expectations as Escalate safety review because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page scientific advice should be turns on in RWE protocol that may not meet regulator expectations.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim 505(b)(2) development lead would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a boxed-warning proposal from the review division and write the one fact that would move scientific advice should be for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.